Sun Pharmaceutical Industries has decided to discontinue certain non-strategic businesses of Ranbaxy Laboratories. This move is a part of the integration process. The company expects to incur certain integration charges in order to generate long-term synergies from this merger. The company has embarked on various consolidation initiatives globally to drive future growth and profitability and to enhance long-term shareholder value.
The company also continues to allocate significant resources to R&D in order to strengthen the specialty pipeline including patented products and complex generics. This will mandate increased R&D investments including that for the development of MK-3222.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
